IVMS Drugs Acting on the Autonomic Nervous System Notes

MARC IMHOTEP CRAY, M.D. © 2009 1 Drugs Acting on the Autonomic Nervous System Notes I. The Peripheral Efferent Nervous System  The autonomic nervous system (ANS) controls involuntary activity (Fig. 2-1, Table 2-1). o Parasympathetic nervous system (PNS)  Long preganglionic axons originate from neurons in the cranial and sacral areas of the spinal cord and, with few exceptions, synapse on neurons in ganglia located close to or within the innervated organ.  Short postganglionic axons innervate cardiac muscle, bronchial smooth muscle, and exocrine glands.  Parasympathetic innervation predominates over sympathetic innervation of salivary glands, lacrimal glands, and erectile tissue. o Sympathetic nervous system (SNS)  Short preganglionic axons originate from neurons in the thoracic and lumbar areas of the spinal cord and synapse on neurons in ganglia located outside of, but close to, the spinal cord. The adrenal medulla, anatomically considered a modified ganglion, is innervated by sympathetic preganglionic axons.  Long postganglionic axons innervate many of the same tissues and organs as the parasympathetic nervous system.  Innervation of thermoregulatory sweat glands is anatomically sympathetic, but the postganglionic nerve fibers are cholinergic and release acetylcholine as the neurotransmitter o Enteric nervous system (ENS)  Considered a third branch of the ANS  Highly organized, semiautonomous, neural complex localized in the gastrointestinal system  Receives preganglionic axons from the PNS and postganglionic axons from the SNS  Nerve terminals contain peptides and purines as neurotransmitters.  The somatic nervous system (Fig. 2-1) controls voluntary activity. This system contains long axons that originate in the spinal cord and directly innervate skeletal striated muscle.  Neurotransmitters of the autonomic and somatic nervous systems (Fig. 2-1) o Acetylcholine (ACh)  Acetylcholine is released by exocytosis from nerve terminals. P.26 MARC IMHOTEP CRAY, M.D. © 2009 2 Figure 2-1 Organization of the autonomic nervous system.  ACh is the neurotransmitter across synapses at the ganglia of the sympathetic and parasympathetic nervous systems and across synapses in tissues innervated by the parasympathetic nervous system and the somatic nervous system.  ACh is synthesized in nerve terminals by the cytoplasmic enzyme choline acetyltransferase (ChAT), which catalyzes the transfer of an acetate group from acetyl coenzyme A (acetyl CoA) to choline that has been transported into ―cholinergic‖ neurons by a sodium-dependent membrane carrier that can be blocked by hemicholinium.  ACh is stored in nerve terminal vesicles that, through calcium-dependent exocytosis, are released by nerve action potentials. On release, a step blocked by botulinum toxin, ACh is rapidly hydrolyzed and inactivated by tissue acetylcholinesterase (AChE) and also by nonspecific butyrylcholinesterase (pseudocholinesterase) to choline and acetate.  ACh is not administered parenterally for therapeutic purposes because it is hydrolyzed nearly instantly by butyrylcholinesterase. o Norepinephrine and epinephrine are catecholamines, possessing a catechol nucleus and an ethylamine side chain.  Storage and release  Norepinephrine is stored in vesicles that, through a calcium-dependent process, release their contents by exocytosis from nerve terminals at postganglionic nerve endings of the MARC IMHOTEP CRAY, M.D. © 2009 3 sympathetic nervous system (except at thermoregulatory sweat glands, where ACh is the neurotransmitter).  Norepinephrine release can be blocked by such drugs as bretylium and guanethidine.  Norepinephrine also exists in a nonvesicular cytoplasmic pool that is released by indirectly acting sympathomimetic amines (e.g., tyramine, amphetamine, ephedrine) by a process that is not calcium dependent.  Norepinephrine and some epinephrine are released from adrenergic nerve endings in the brain. In the periphery, epinephrine, along with some norepinephrine, is the P.27 major catecholamine released from adrenal medullary chromaffin cells into the general circulation, where they function as hormones. Table 2.1 Actions of the Autonomic Nervous System on Selected Effector Organs Effector Action of Sympathetic (Thoracolumbar) Division Action of Parasympathetic (Craniosacral) Division Eye (pupil) Dilation (ex) Constriction (ex) Heart Rate Acceleration (ex) Slowing (in) Contractility Increased (ex) Decreased (in) Arterioles Skin and most others Constriction (ex) — Skeletal muscle Dilation (ex) — Glands Salivary Viscid secretion (ex) Watery secretion (ex) Lacrimal — Secretion (ex) Sweat Secretion (ex) — Bronchial muscle Relaxation (in) Contraction (ex) GI tract Muscle wall Relaxation (in) Contraction (ex) Sphincters Contraction (ex) Relaxation (in) Urinary bladder Fundus Relaxation (in) Contraction (ex) Trigone; sphincter Contraction (ex) Relaxation (in) Penis Ejaculation (ex) Erection (in) Uterus Relaxation (in) — Metabolism Liver Gluconeogenesis (ex) — Glycogenolysis (ex) — MARC IMHOTEP CRAY, M.D. © 2009 4 Kidney Renin secretion(ex) — Fat Cells Lipolysis (ex)  Biosynthesis of catecholamines (Fig. 2-2)  In prejunctional nerve endings, tyrosine is hydroxylated by tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of catecholamines, to form dihydroxyphenylalanine (dopa); dopa is then decarboxylated by dopa decarboxylase to form dopamine.  Dopamine is transported into vesicles, a step blocked by reserpine, where it is hydroxylated on the side chain by dopamine β-hydroxylase to form norepinephrine.  In certain areas of the brain and in the adrenal medulla, norepinephrine is methylated on the amine group of the side chain by phenylethanolamine-N-methyltransferase (PNMT) to form epinephrine.  Termination  The action of norepinephrine is terminated primarily by active transport from the cytoplasm into the nerve terminal (uptake 1), a process that is inhibited by cocaine and tricyclic antidepressant agents such as imipramine. Norepinephrine is then transported by a second carrier system into storage vesicles.  Another active transport system (uptake 2) is located on glia and smooth muscle cells.  There is also some simple diffusion away from the synapse.  Norepinephrine and epinephrine also are oxidatively deaminated by mitochondrial monoamine oxidase (MAO) in nerve terminals and effector cells, notably in the liver and intestine. Isoforms of MAO (A and B) have been identified. Dopamine is metabolized primarily by MAO-B. MARC IMHOTEP CRAY, M.D. © 2009 5 Figure 2-2 Biosynthesis of catecholamines.  P.28   Nerve cells and effector cells contain catechol-O-methyltransferase (COMT), which metabolizes catecholamines. Metabolites, including 3-methoxy-4-hydroxymandelic acid (VMA), provide a measure of catecholamine turnover in the body.  Receptors of the nervous system o Cholinoceptors  Nicotinic receptors: Cholinoceptors that are activated by the alkaloid nicotine (Fig. 2-1)  Nicotinic receptors are localized at myoneural junctions of somatic nerves and skeletal muscle (NM), autonomic ganglia (NG), including the adrenal medulla, and certain areas in the brain.  Nicotinic receptors consist of five protein subunits in skeletal muscle (e.g., α (2), β, γ, δ) and two protein subunits in ganglia (α and β) that form ligand-gated (i.e., regulated) ion channel pores in the cell membranes (see Fig. 1-1A).  In skeletal muscle, ACh interacts with nicotinic receptors (one molecule of ACh per α subunit) to open channels that permit passage of ions, mostly Na+. The Na+ current produces membrane depolarization and a propagated action potential through the transverse tubules of skeletal muscle, resulting in the release of Ca2+ from the sarcoplasmic reticulum and, through a further series of chemical and mechanical events, muscle contraction. Hydrolysis of ACh by AChE results in muscle cell repolarization. MARC IMHOTEP CRAY, M.D. © 2009 6  The continued presence of some nicotinic agonists at nicotinic receptors, or excessive cholinergic stimulation, can lead to a ―depolarizing blockade‖ (phase I block), in which normal depolarization is followed by persistent depolarization. During phase I block, skeletal muscle is unresponsive to either neuronal stimulation or direct stimulation.  The selective nicotinic receptor antagonists tubocurarine and trimethaphan can block the effect of ACh at skeletal muscle and autonomic ganglia, respectively. P.29  Muscarinic receptors: Cholinoceptors that are activated by the alkaloid muscarine (Fig. 2-1)  Muscarinic receptors are localized on numerous autonomic effector cells, including cardiac atrial muscle and cells of the sinoatrial (SA) and atrioventricular (AV) nodes, smooth muscle, exocrine glands, and vascular endothelium (mostly arterioles), although the latter do not receive parasympathetic innervation, as well as certain areas in the brain.  Muscarinic receptors consist of at least three functional receptor subtypes (M1–M3). M1 receptors are found in sympathetic postganglionic neurons and in central nervous system neurons; M2 receptors are found in cardiac and smooth muscle; and M3 receptors are found in glandular cells (e.g., gastric parietal cells, and the vascular endothelium and vascular smooth muscle).  ACh interacts with M1 and M3 muscarinic cholinoceptors to increase phosphatidylinositol (PI) turnover and Ca2+ mobilization (see Fig. 1-1D).  By activation of G protein (Gq), the interaction of ACh with M1 and M3 muscarinic cholinoceptors stimulates polyphosphatidylinositol phosphodiesterase (phospholipase C), which hydrolyzes PI to inositol trisphosphate (IP3) and diacylglycerol (DAG).  IP3 mobilizes intracellular Ca2+ from the endoplasmic and sarcoplasmic reticula, and activates Ca2+-regulated enzymes and cell processes.  Diacylglycerol activates protein kinase C, which results in phosphorylation of cellular enzymes and other protein substrates and the influx of extracellular calcium that results in activation of contractile elements in smooth muscle.  ACh also interacts with M2 muscarinic cholinoceptors to activate G proteins (G1), which leads to inhibition of adenylate cyclase activity with decreased levels of cyclic AMP and to increased K+conductance with effector cell hyperpolarization. MARC IMHOTEP CRAY, M.D. © 2009 7  Cholinergic agonists act on M3 muscarinic receptors of endothelial cells to promote the release of nitric oxide (NO), which diffuses to the vascular smooth muscle and produces relaxation. o Adrenoceptors (Fig. 2-1)  α-Adrenoceptors  α-Adrenoceptors are classified into two major receptor subtypes. α1-Receptors are located in postjunctional effector cells, notably vascular smooth muscle, where responses are mainly excitatory; α2-receptors are located primarily in prejunctional adrenergic nerve terminals, and also in platelets and in beta-cells of the pancreas.  α-Adrenoceptors mediate vasoconstriction (α1), gastrointestinal relaxation (α1), mydriasis (α1), prejunctional inhibition of release of norepinephrine and other neurotransmitters (α2), inhibition of insulin release (α2) and platelet aggregation (α2).  α-Adrenoceptors are distinguished from β-adrenoceptors by their interaction (in descending order of potency), with the adrenergic agonists epinephrine = norepinephrine >> isoproterenol, and by their interaction with relatively selective antagonists such as phentolamine.  α1-Receptors, like muscarinic M1 and M3 cholinoceptors, activate guanine nucleotide-binding proteins (Gq) in many cells, which results in activation of phospholipase C and stimulation of phosphoinositide (PI) hydrolysis that leads to increased formation of inositol trisphosphate (IP3) and mobilization of intracellular stores of Ca2+ and to increased diacylglycerol (DAG) and activation of protein kinase C.  α2-Receptors, like muscarinic M2-cholinoceptors, activate inhibitory guanine nucleotide-binding proteins (Gi), inhibit adenylate cyclase activity, and decrease intracellular cyclic AMP (cAMP) levels and the activity of cAMP-dependent protein kinases (see Fig. 1-1C).  β-Adrenoceptors (Fig. 2-1)  β-Adrenoceptors, located mostly in postjunctional effector cells, are classified into two major receptor subtypes, β1-receptors (primarily excitatory) and β2-receptors (primarily inhibitory). P.30  β1-Receptor subtype  β1-Receptors mediate increased contractility and conduction velocity, fat cell lipolysis, and renin secretion in the kidney.  The β1-receptor subtype is defined by its interaction (in descending order of potency) with the adrenergic agonists isoproterenol > epinephrine = MARC IMHOTEP CRAY, M.D. © 2009 8 norepinephrine and by its interaction with relatively selective antagonists such as atenolol.  β2-Receptor subtype  β2-Receptors mediate vasodilation and intestinal, bronchial, and uterine smooth muscle relaxation.  The β2-receptor subtype is defined by its interaction (in descending order of potency) with the adrenergic agonists isoproterenol = epinephrine >> norepinephrine.  β-Receptor activation  β-Receptors activate guanine nucleotide-binding proteins (Gs; see Fig. 1-1B).  Activation stimulates adenylate cyclase activity and increases intracellular cAMP levels and the activity of cAMP-dependent protein kinases. Adrenoceptor-mediated changes in the activity of protein kinases (and also levels of intracellular Ca2+) bring about changes in the activity of specific enzymes and structural and regulatory proteins, resulting in modification of cell and organ activity. II. Parasympathomimetic Drugs  Direct-acting muscarinic cholinoceptor agonists o Action and chemical structure  Direct-acting parasympathomimetic drugs act at muscarinic cholinoceptors to mimic many of the physiologic effects that result from stimulation of the parasympathetic division of the autonomic nervous system (see Fig. 2-1).  Bethanechol and carbachol are choline esters with a quaternary ammonium group that are structurally similar to acetylcholine but more resistant to hydrolysis by acetylcholinesterase. The β-methyl group of bethanechol substantially reduces its activity at nicotinic receptors.  Pilocarpine is a tertiary amine alkaloid. o Pharmacologic effects (Tables 2-2 and Tables 2-3) P.31 MARC IMHOTEP CRAY, M.D. © 2009 9 Table 2.2 Actions of Direct-Acting Cholinoceptor Agonists Effector Effects of Muscarinic Agonists Heart (rate, conduction velocity)a Decrease Arterioles (tone) Decrease Blood pressure Decrease Pupil size Decrease Salivation Increase Lacrimation Increase Bronchial tone Increase Intestine (motility) Increase GI secretions Increase Urinary bladder Body (tone) Increase Sphincter Decrease aResponses (e.g., heart rate) may be affected by reflexes. Table 2.3 Effects of Muscarinic Cholinoceptor and Adrenoceptor Agonists on Smooth Muscles of the Eye Type of Drug Muscle Effect Result Muscarinic agonist Iris circular (constrictor) Ciliary circular Contraction Contraction Miosis Accommodation Muscarinic antagonist Iris circular (constrictor) Ciliary circular Relaxation Relaxation Mydriasis Cycloplegia α-Adrenergic agonist Iris radial (dilator) Ciliary circular Contraction None Mydriasis None  Eye  Direct-acting muscarinic cholinoceptor agonists contract the circular smooth muscle fibers of the ciliary muscle and iris to produce, respectively, a spasm of accommodation and an increased outflow of aqueous humor into the canal of Schlemm, resulting in a reduction in intraocular pressure.  These drugs contract the smooth muscle of the iris sphincter to cause miosis.  Cardiovascular system  Direct-acting muscarinic cholinoceptor agonists produce a negative chronotropic effect (reduced SA node activity).  These drugs decrease conduction velocity through the AV node.  These drugs have no effect on force of contraction because there are no muscarinic receptors on, or parasympathetic innervation of, ventricles.  Direct-acting muscarinic cholinoceptor agonists produce vasodilation that results primarily from their action on endothelial cells to promote the release of nitric oxide (NO), which diffuses to the vascular smooth muscle and produces relaxation. Vascular smooth muscle has muscarinic receptors but no parasympathetic innervation. The resulting decrease in blood pressure can result in a reflex increase in heart rate. (Intravenous infusion of low doses of ACh causes a reflex sympathetic-stimulated increase in heart rate; higher doses directly inhibit heart rate.)  Gastrointestinal tract MARC IMHOTEP CRAY, M.D. © 2009 10  Direct-acting muscarinic cholinoceptor agonists increase smooth muscle contractions and tone, with increased peristaltic activity and motility.  These drugs increase salivation and acid secretion.  Urinary tract  Direct-acting muscarinic cholinoceptor agonists increase contraction of the ureter and bladder smooth muscle.  These drugs increase sphincter relaxation.  Respiratory system effects of direct-acting muscarinic cholinoceptor agonists include bronchoconstriction with increased resistance and increased bronchial secretions.  Other effects  These drugs increase the secretion of tears from lacrimal glands and increase sweat gland secretion.  These drugs produce tremor and ataxia. o Specific drugs and their therapeutic uses. These drugs are used primarily for diseases of the eye, gastrointestinal tract, urinary tract, the neuromuscular junction, and the heart (Table 2-4).  Bethanechol [Urecholine]  Bethanechol is used to stimulate smooth muscle motor activity of the urinary tract to prevent urine retention.  It is used occasionally to stimulate gastrointestinal smooth muscle motor activity for postoperative abdominal distention and for gastric atony following bilateral vagotomy (in the absence of obstruction). P.32 Table 2.4 Selected Therapeutic Uses of Selected Direct-Acting Cholinoceptor Agonists Agent Conditions/Disorders Bethanechol Prevent urine retention; postoperative abdominal distension; gastric atony Methacholine Diagnostic for bronchial hypersensitivity Pilocarpine Open-angle glaucoma; acute narrow-angle glaucoma; Sjögren syndrome  Bethanechol is administered orally or subcutaneously, not by IV or IM route, because parenteral administration may cause cardiac arrest.  This drug has low lipid solubility and is poorly absorbed from the GI tract. When given orally, GI effects predominate, and there are relatively minor cardiovascular effects.  Bethanechol has limited distribution to the CNS.  It is resistant to hydrolysis by AChE and plasma cholinesterase and thus has a longer duration of action than ACh (2–3 hours). MARC IMHOTEP CRAY, M.D. © 2009 11  Methacholine [Mecholyl] is occasionally used to diagnose bronchial hypersensitivity and asthmatic conditions.  Pilocarpine  Pilocarpine is occasionally used topically for open-angle glaucoma, either as eyedrops or as a sustained-release ocular insert [Ocusert]. β-Adrenergic receptor antagonists such as timolol and betaxolol and prostaglandin analogues such as latanoprost are the drugs of choice to treat open-angle glaucoma. Other drug classes used include α-adrenergic receptor agonists such as epinephrine and diuretics such as acetazolamide.  When used prior to surgery to treat acute narrow-angle glaucoma (a medical emergency), pilocarpine is often given in combination with an indirectly acting muscarinic agonist such as physostigmine.  Pilocarpine and cevimeline [Evoxac], a newer muscarinic receptor agonist, increase salivary secretion. They are used to treat Sjögren syndrome.  Pilocarpine is a tertiary amine that is well absorbed from the gastrointestinal tract and enters the CNS.  Carbachol is rarely used except if pilocarpine is ineffective as a treatment for open-angle glaucoma. o Adverse effects and contraindications  The adverse effects associated with direct-acting muscarinic cholinoceptor agonists are extensions of their pharmacologic activity. The most serious include nausea, vomiting, sweating, salivation, bronchoconstriction, decreased blood pressure, and diarrhea, all of which can be blocked or reversed by atropine. Systemic effects are minimal for drugs applied topically to the eye.  These drugs are contraindicated in the presence of peptic ulcer, because they increase acid secretion, asthma, cardiac disease, and Parkinson's disease. They are not recommended in hyperthyroidism because they predispose to arrhythmia; they are also not recommended when there is mechanical obstruction of the gastrointestinal or urinary tract.  Indirect-acting parasympathomimetic agents o Chemical structure  Edrophonium is an alcohol with a quaternary ammonium group.  Neostigmine and physostigmine are examples of carbamic acid esters of alcohols (carbamates) with either quaternary or tertiary ammonium groups.  Echothiophate and isoflurophate are examples of organic derivatives of phosphoric acid. o Mechanism of action (Fig. 2-3A and B)  Indirect-acting parasympathomimetic agents inhibit AChE and increase ACh levels at both muscarinic and nicotinic cholinoceptors to mimic many of the physiologic effects that result from stimulation of the parasympathetic division of the autonomic nervous system. P.33 MARC IMHOTEP CRAY, M.D. © 2009 12 Figure 2-3 Hydrolysis of acetylcholine by acetylcholinesterase.  ACh interacts with AChE at two sites: The N+ of choline (ionic bond) binds to the anionic site, and the acetyl ester binds to the esteratic site (serine residue). As ACh is hydrolyzed, the serine-OH side chain is acetylated and free choline is released. Acetyl-serine is hydrolyzed to serine and acetate. The half-life (t1/2) of acetylserine hydrolysis is 100–150 microseconds.  Edrophonium [Tensilon] acts at the same sites of AChE to competitively inhibit ACh hydrolysis by the following processes:  N+ of edrophonium binds the anionic site.  Phenolic hydroxyl of edrophonium interacts with histidine imidazolium N+ of the esteratic site.  Edrophonium has a short duration of action (5–15 min). MARC IMHOTEP CRAY, M.D. © 2009 13  Neostigmine [Prostigmin], physostigmine [Eserine, Antilirium], and demecarium [Humorsol], like ACh, interact with AChE and undergo a two-step hydrolysis. However, the serine residue of the enzyme is covalently carbamylated rather than acetylated. Hydrolysis of the carbamylserine residue is much slower than that of acetylserine (30 min-6 h). P.34  Neostigmine, physostigmine, and demecarium also have direct agonist action at skeletal muscle nicotinic cholinoceptors.  These drugs differ in absorption as follows:  Because of its quaternary ammonium structure, neostigmine is poorly absorbed from the gastrointestinal tract and has negligible distribution into the CNS.  Physostigmine is well absorbed after oral administration, and it enters the CNS.  Echothiophate [Phospholine] and isoflurophate [Floropryl], irreversible and toxic organophosphate cholinesterase inhibitors, result in phosphorylation of AChE rather than acetylation. With time, the strength of the bond increases (―aging‖), and AChE becomes irreversibly inhibited. The enzyme can be reactivated within the first 30 minutes by pralidoxime. Hydrolysis of the covalent alkylphosphoryl-serine bond takes days.  These drugs differ in absorption and distribution as follows:  Echothiophate is poorly absorbed from the gastrointestinal tract and has negligible distribution into the CNS.  Isoflurophate is highly lipid soluble and is well absorbed across all membranes, including skin.  Pralidoxime [Protopam]  Pralidoxime is an AChE reactivator. It must be administered IV within minutes of exposure to an AChE inhibitor because it is effective only prior to ―aging.‖  Pralidoxime acts as an antidote for insecticide and nerve gas poisoning. It binds the anionic site and undergoes a nucleophilic reaction with P=O group of alkylphosphorylated serine to cause hydrolysis of the phosphoserine bond that is at least 106 times faster than that occurring in water.  This drug is most effective at the neuromuscular junction. It is ineffective in the CNS and against carbamylated AChE.  Pralidoxime produces few adverse effects in normal doses. o Pharmacologic effects (Table 2-2)  With the major exception of arteriole tone and blood pressure, where their effects are less pronounced, the pharmacologic effects of indirect-acting parasympathomimetic agents are similar to those of direct-acting muscarinic cholinoceptor agonists.  By increasing ACh at the neuromuscular junction, these drugs increase the contraction strength of skeletal muscle. The effect is more MARC IMHOTEP CRAY, M.D. © 2009 14 pronounced if muscle contraction is already weak, as occurs in myasthenia gravis. o Therapeutic uses  Glaucoma  Physostigmine is often used concurrently with pilocarpine for maximum effect in the treatment of acute angle-closure glaucoma, a medical emergency.  Physostigmine, demecarium, echothiophate, and other cholinesterase inhibitors, have been largely replaced for the treatment of chronic open-angle glaucoma by topical β-adrenergic receptor antagonists such as timolol and betaxolol, and by prostaglandin analogues such as latanoprost. They are used when other drugs are ineffective. Prolonged use may increase the possibility of cataracts.  Gastrointestinal and urinary tract atony can be treated with neostigmine, which is used much like bethanechol.  Myasthenia gravis  Myasthenia gravis is an autoimmune disease in which antibodies complex with nicotinic receptors at the neuromuscular junction to cause skeletal muscle weakness and fatigue. Neostigmine, or the related AChE inhibitors pyridostigmine [Mestinon, Regonol] or ambenonium [Mytelase], is used to increase ACh levels at the neuromuscular junction to activate fully the remaining receptors.  Myasthenia gravis can be diagnosed using the Tensilon test, which can also assess the adequacy of treatment with AChE inhibitors. Small doses of edrophonium improve muscle strength in untreated patients with myasthenia or in treated patients in whom AChE inhibition is inadequate. If there is no effect, or if muscle weakness increases, the dose of the AChE inhibitor is too high (excessive ACh stimulation at the neuromuscular junction results in a depolarizing blockade). P.35  Atropine can be used to control excessive muscarinic stimulation by AChE inhibitors.  Tolerance may develop to long-term use of the AChE inhibitors.  Neostigmine or edrophonium can be used following surgery to reverse neuromuscular blockade and paralysis resulting from adjunct use of nondepolarizing agents.  Atropine and scopolamine poisoning can be treated with physostigmine, which reverses the central and (to some extent) the peripheral effects of competitive muscarinic antagonists. o Adverse effects and toxicity  The adverse effects associated with indirect-acting sympathomimetic agents are an extension of pharmacologic activity and arise from excessive cholinergic stimulation. MARC IMHOTEP CRAY, M.D. © 2009 15  Adverse effects include muscarinic effects similar to those of direct-acting cholinergic drugs and nicotinic effects such as muscle weakness, cramps and fasciculations, excessive bronchial secretions, convulsions, coma, cardiovascular collapse, and respiratory failure.  Many lipid-soluble organophosphates are used as insecticides (e.g., malathion) or nerve gases (e.g., sarin) and may be absorbed in sufficient quantities from the skin or lungs to cause cholinergic intoxication. Treatment includes the following steps:  Maintain respiration and decontaminate to prevent further absorption.  Administer atropine parenterally to inhibit muscarinic effects.  Administer pralidoxime within minutes of exposure. III. Muscarinic-Receptor Antagonists  Mechanism and chemical structure (Table 2-5) o Muscarinic-receptor antagonists are competitive antagonists of ACh at all muscarinic cholinoceptors. o Atropine, the prototype muscarinic-receptor antagonist, scopolamine, homatropine, cyclopentolate [Cyclogyl], tridihexethyl [Pathilon], dicyclomine [Bentyl], oxybutynin [Ditropan], tolterodine [Detrol], and tropicamide [Mydriacyl] are tertiary amine alkaloids. o Methantheline [Banthine], propantheline [Pro-Banthine], glycopyrrolate [Robinul] clidinium [Quarzan], mepenzolate [Cantil], and ipratropium [Atrovent] are quaternary amines. Table 2.5 Properties of Some Cholinoceptor Blocking Agents Receptors Agent Action Muscarinic Nicotinic Comments Atropine Competitive antagonist + Prototype muscarinic;cholinoceptor blocking agent Scopolamine Competitive antagonist + Actions similar to those of atropine Propantheline Competitive antagonist + Peripheral-acting cholinoceptor blocking agent Trimethaphan Competitive, nondepolar-izing antagonist + Peripheral-acting gan-glionic blocking agent Cisatracurium Competitive, nondepolar-izing antagonist at motor endplate + Neuromuscular junction blocking agent Succinylcholine Depolarizing agonist at motor endplate + Neuromuscular junction blocking agent P.36  Pharmacologic effects MARC IMHOTEP CRAY, M.D. © 2009 16 o Eye (Table 2-3)  Muscarinic-receptor antagonists produce cycloplegia by blocking parasympathetic tone, leading to paralysis of the ciliary muscle and loss of accommodation.  These drugs produce mydriasis by blocking parasympathetic tone to the iris circular (constrictor) muscle. Unopposed sympathetic stimulation of the radial muscle results in dilation of the pupil. o Cardiovascular system  Muscarinic-receptor antagonists increase heart rate due to cholinergic blockade at the SA node.  These drugs dilate blood vessels in facial blush area (atropine flush), which is not related to the antagonist action. o Gastrointestinal tract  Muscarinic-receptor antagonists decrease salivation.  These drugs reduce peristalsis, resulting in prolonged gastric emptying and intestinal transit.  They also reduce gastric acid secretion. o Other effects  Muscarinic-receptor antagonists produce some bronchodilation and decrease mucus secretion.  These drugs relax the ureters and bladder in the urinary tract and constrict the urinary sphincter.  Tertiary amines can produce restlessness, headache, excitement, hallucinations, and delirium.  These drugs produce anhidrosis and dry skin because of the inhibition of sympathetic cholinergic innervation of the sweat glands.  Pharmacologic properties o Unlike quaternary ammonium drugs (10–30% absorption), most tertiary muscarinic-receptor antagonists are well absorbed across the gastrointestinal tract or mucosal surfaces and distribute throughout the body, including the brain. o Atropine and scopolamine have relatively long durations of action.  Therapeutic uses (Table 2-6) o Eye  Shorter-acting muscarinic-receptor antagonists are administered topically as eyedrops or as ointments for refractive measurements and for ophthalmoscopic examination of the retina and other structures of the eye (α-adrenoceptor agonists, such as phenylephrine, are used for simple funduscopic examination without cycloplegia).  Longer-acting muscarinic-receptor antagonists (such as homatropine) are generally preferred as adjuncts to phenylephrine to prevent synechia formation in anterior uveitis and iritis. o Cardiovascular system uses include the administration of these drugs as a treatment for acute myocardial infarction with accompanying bradycardia and hypotension or arrhythmias. MARC IMHOTEP CRAY, M.D. © 2009 17 Table 2.6 Selected Therapeutic Use of Muscarinic Cholinoceptor Antagonists Organ/System Therapeutic Use Eye Refractive measurement; ophthalmologic examination, uveitis and iritis Heart Acute myocardial infarction Bladder Urinary urgency Lung Surgical anesthesia to suppress secretions CNS Motion sickness (scopolamine); Parkinson's disease Multiple organs/systems Cholinergic poisoning  P.37  o Urinary tract uses of atropine and other muscarinic-receptor antagonists include the administration of these drugs for symptomatic treatment of urinary urgency in inflammatory bladder disorder. Oxybutynin [Ditropan], tolterodine [Detrol], and propiverine [Detrunorm] are additional agents in this class used to treat certain urinary disorders. o Central nervous system  Antimuscarinic drugs, benztropin, biperidin, trihexphenidyl, and others, are used as adjunct to levodopa therapy for some patients with Parkinson's disease (see Chapter 5).  Scopolamine (used orally, intravenously, or transdermally) prevents motion sickness by blocking muscarinic receptors in the vestibular system and in the CNS. o Respiratory system  Atropine and scopolamine are used to suppress bronchiolar secretions during surgical and spinal anesthesia and to prevent the muscarinic effects of AChE inhibitors used to reverse muscle paralysis at the end of surgery. Scopolamine also has additional amnestic and sedative properties.  Ipratropium is used as an inhalant to treat reactive airway disease such as asthma and chronic obstructive pulmonary disease (COPD). o Other uses  Tertiary agents such as atropine are used to block peripheral and CNS effects due to cholinergic excess, especially those caused by poisoning with AChE inhibitor-containing insecticides and muscarine-containing mushrooms.  Adverse effects and contraindications o The adverse effects of muscarinic-receptor antagonists are extensions of pharmacologic activity and include mydriasis, cycloplegia, dry eyes, tachycardia, dry mouth, elevated temperature, dry skin, urine retention, agitation, hallucinations, and delirium (―hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter‖). Treatment is symptomatic. Physostigmine administration for treatment of tertiary amine overdose is not recommended. Neostigmine is used to treat poisoning with quaternary muscarinic-receptor antagonists. o Contraindications (relative) MARC IMHOTEP CRAY, M.D. © 2009 18  These drugs are contraindicated in glaucoma, particularly angle-closure glaucoma, in gastrointestinal and urinary tract obstruction (e.g., prostatic hypertrophy), and in gastric ulcer. o Drug interactions of muscarinic-receptor antagonists include the production of additive effects when administered with other drugs with muscarinic-receptor antagonist activity (certain antidepressants, antipsychotics, and antihistamines). IV. Ganglionic-Blocking Drugs  Mechanism and therapeutic uses (see Table 2-5) o Ganglionic-blocking drugs, trimethaphan [Arfonad] and mecamylamine [Inversine], inhibit the effect of ACh at nicotinic receptors by acting competitively (nondepolarizing blockade) at both sympathetic and parasympathetic autonomic ganglia. Because of a lack of selectivity and numerous adverse effects they are used rarely in the clinical setting (hypertensive emergencies). V. Skeletal Muscle Relaxants  Classification and structure o Neuromuscular junction-blocking drugs (see Table 2-5)  Classified as either nondepolarizing or depolarizing types, neuromuscular junction-blocking drugs cause neuromuscular paralysis. They are structurally similar to ACh.  Nondepolarizing neuromuscular junction-blocking drugs, the prototype is tubocurarine, are arranged in a bulky, rigid conformation. P.38  Depolarizing neuromuscular junction-blocking drugs have a linear structure. Succinylcholine, the only one used clinically, is composed of two ACh molecules linked end to end. o Spasmolytic drugs act to reduce abnormal muscle tone without paralysis. These drugs increase or mimic the activity of γ-aminobutyric acid (GABA) in the spinal cord and brain or interfere with the release of calcium in skeletal muscle.  Nondepolarizing agents o Mechanism  Nondepolarizing agents competitively inhibit the effect of ACh at the postjunctional membrane nicotinic receptor of the neuromuscular junction. There is some prejunctional inhibition of ACh release.  These agents prevent depolarization of the muscle and propagation of the action potential. o Pharmacologic properties  Nondepolarizing agents are administered parenterally and are generally used for long-term motor paralysis. Paralysis and muscle relaxation occur within 2–5 minutes.  These agents are quaternary ammonium compounds with poor lipid solubility, which limits penetration into the CNS. MARC IMHOTEP CRAY, M.D. © 2009 19  Nondepolarizing agents have durations of action that range from 20–90 minutes, which can be extended by supplemental fractional dosing and is increased by larger initial doses (although this also increases the likelihood of adverse effects).  Most nondepolarizing agents are metabolized by the liver or are excreted unchanged. The duration of action may be prolonged by hepatic or renal disease. o Specific drugs (Table 2-7)  Tubocurarine (prototype), an isoquinoline derivative, is seldom used clinically at this time.  Metocurine [Metubine] is a derivative of tubocurarine. It has the same properties, but with less histamine release and thus less hypotension and bronchoconstriction. Metocurine has a long duration of action (>40 min).  Atracurium [Tracrium]  Atracurium is structurally related to tubocurarine, with an intermediate duration of action (20–40 min).  Atracurium has little vagolytic or ganglion-blocking activity. It causes some histamine release.  Atracurium is inactivated spontaneously in plasma by nonenzymatic hydrolysis that is delayed by acidosis. Its duration of action is reduced by hyperventilation-induced respiratory alkalosis.  Laudanosine, a breakdown product of atracurium, may accumulate to cause seizures.  Cisatracurium [Nimbex] is a stereoisomer of atracurium that releases less histamine and forms less laudanosine. It is replacing atracurium use in clinical practice.  Other available isoquinoline derivatives similar to atracurium include short-acting (10–20 min) mivacurium [Mivacron], which is rapidly hydrolyzed by plasma cholinesterase (pseudocholinesterase), has a short duration of action, and produces moderate histamine release at high doses, and doxacurium [Nuromax], which is stable in plasma, has a long duration of action (90–120 min), is excreted unchanged, and is devoid of vagolytic activity.  Pancuronium [Pavulon]  Pancuronium has a steroid nucleus with two attached quaternary amine groups.  This drug has a long duration of action (120–180 min).  Pancuronium produces no histamine release or ganglia blockade.  Pancuronium causes a moderate tachycardia, primarily due to cardiac muscarinic receptor blockade.  This drug is excreted by the kidney with only minimal hepatic metabolism.  Vecuronium [Norcuron]  Vecuronium is a steroid derivative that has an intermediate duration of action (30–40 min). P.39 MARC IMHOTEP CRAY, M.D. © 2009 20 P.40 Table 2.7 Properties of Some Skeletal Muscle Relaxants Cardiac Nondepolarizing Agent Duration of Action Ganglion Blockade Histamine Release Muscarinic Receptors Comments Tubocurarinea Long + ++ — Prototype Metocurinea Long + + — Less hypotension and bronchoconstriction than tubocurarine Atracuriuma Intermediate — + — Inactivated spontaneously in plasma; laudanosine, a breakdown product, may cause seizures. Cisatracuriuma Intermediate — — — Less laudanosine formed than atracurium. Mivacuriuma Short — ++ — Hydrolyzed by plasma cholinesterase. Pancuroniumb Long — — ++ Increased heart rate Vecuroniumb Intermediate — — — Metabolized by liver Depolarizing Agent Succinylcholine Very short ++ + ++ Hydrolyzed by cholinesterase; malignant hyperthermia is a rare, potentially fatal complication aIsoquinoline derivative. bSteroid derivative. MARC IMHOTEP CRAY, M.D. © 2009 21  Vecuronium has little vagolytic, histaminic, or ganglion-blocking activity.  This drug is primarily metabolized by the liver.  Other available agents with a steroid nucleus include rocuronium [Zemuron], a derivative of vecuronium with an intermediate duration of action (30–40 min), and pipecuronium [Arduan], with a long duration of action (80–100 min) and that undergoes hepatic and renal clearance. o Therapeutic uses  Nondepolarizing agents are used during surgery as adjuncts to general anesthetics to induce muscle paralysis and muscle relaxation. The order of muscle paralysis is small, rapidly contracting muscles (e.g., extrinsic muscles of the eye) before slower contracting muscle groups (e.g., face and extremities), followed by intercostal muscles, and then the diaphragm. Recovery of muscle function is in reverse order, and respiration often must be assisted.  These agents are also used for muscle paralysis in patients when it is critical to control ventilation, and they are used to control muscle contractions during electroconvulsive therapy. o Reversal of nondepolarizing drug blockade  AChE inhibitors, such as neostigmine, are administered for pharmacologic antagonism to reverse residual postsurgical muscarinic receptor blockade and avoid inadvertent hypoxia or apnea. o Adverse effects and contraindications (Table 2-7)  Cardiovascular system  Nondepolarizing agents that are isoquinoline derivatives may produce hypotension due to histamine release and ganglionic-blocking activity.  Nondepolarizing agents that are steroid derivatives may produce tachycardia due to vagolytic activity, leading to potential arrhythmias. These drugs should be used cautiously in patients with cardiovascular disease.  Respiratory system  Some nondepolarizing agents that are isoquinoline derivatives can produce bronchospasm in sensitive individuals due to histamine release. Agents that release histamine are contraindicated for asthmatic patients and patients with a history of anaphylactic reactions. o Drug interactions  General inhalation anesthetics, particularly isoflurane, increase the neuromuscular blocking action of nondepolarizing agents. The dose of the neuromuscular junction-blocking drug may have to be reduced.  Aminoglycoside antibiotics, among others, inhibit prejunctional ACh release and potentiate the effect of nondepolarizing and depolarizing neuromuscular junction-blocking drugs.  Depolarizing agents(Table 2-7) include succinylcholine [Anectine], the only depolarizing drug of clinical importance. Succinylcholine consists of two ACh molecules joined together. o Mechanism of action  Succinylcholine is a nicotinic receptor agonist that acts at the motor endplate of the neuromuscular junction to produce persistent stimulation MARC IMHOTEP CRAY, M.D. © 2009 22 and depolarization of the muscle, thus preventing stimulation of contraction by ACh.  After a single IV injection and depolarization of the muscle, there are initial muscle contractions or fasciculations (in the first 30–60 s) that may be masked by general anesthetics. Because succinylcholine is metabolized more slowly than ACh at the neuromuscular junction, the muscle cells remain depolarized (depolarizing or phase I block) and unresponsive to further stimulation, resulting in a flaccid paralysis (5–10 min).  With continuous long-term exposure (45–60 min), the muscle cells repolarize. However, they cannot depolarize again while succinylcholine is present and, therefore, remain unresponsive to ACh (desensitizing or phase II block).  AChE inhibition will enhance the initial phase I block by succinylcholine, but can reverse phase II block. P.41 o Pharmacologic properties  Succinylcholine has a rapid onset and short duration of action. Action is rapidly terminated (5–10 min) by hydrolysis by plasma and liver cholinesterase.  Reduced plasma cholinesterase synthesis in end-stage hepatic disease or reduced activity following the use of irreversible AChE inhibitors may increase the duration of action. o Therapeutic uses of succinylcholine include the administration of the drug to induce brief paralysis in short surgical procedures such as tracheal intubation or in electroconvulsive shock therapy. o Adverse effects  Postoperative muscle pain at higher doses  Hyperkalemia  Hyperkalemia results from loss of tissue potassium during depolarization.  Risk of hyperkalemia is enhanced in patients with burns, muscle trauma, or spinal cord transections.  Hyperkalemia can be life-threatening, leading to cardiac arrest and circulatory collapse.  Malignant hyperthermia  Malignant hyperthermia is a rare but often fatal complication in susceptible patients that results from a rapid increase in muscle metabolism. About 50% of patients are genetically predisposed, with mutations in the skeletal muscle Ca2+-release channel of the sarcoplasmic reticulum (ryanodine receptor, RYR1).  Malignant hyperthermia is most likely to occur when succinylcholine is used with the general anesthetic halothane. MARC IMHOTEP CRAY, M.D. © 2009 23  It is characterized by tachycardia and, among other manifestations, intense muscle spasm that results in a rapid and profound hyperthermia.  Drug treatment is with dantrolene (see below).  Prolonged paralysis that may result in apnea (lasting 1–4 h) in a small percentage of patients (1/10,000) with genetically atypical or low levels of plasma cholinesterase. Mechanical ventilation is necessary.  Bradycardia from direct stimulation of muscarinic cholinoceptor stimulation that is prevented by atropine  Increased intraocular pressure as a result of extraocular muscle contractions; use of succinylcholine may be contraindicated for penetrating eye injuries.  Succinylcholine produces increased intragastric pressure, which may result in fasciculations of abdominal muscles and a danger of aspiration. o Spasmolytic drugs  These muscle relaxants reduce increased muscle tone associated with a variety of nervous system disorders (e.g., cerebral palsy, multiple sclerosis, spinal cord injury, and stroke) that result in loss of supraspinal control and hyperexcitability of α-and γ-motoneurons in the spinal cord, causing abnormal skeletal muscle, bowel, and bladder function.  Selected drugs  Dantrolene [Dantrium]  Dantrolene acts directly on muscle to reduce skeletal muscle contractions.  Dantrolene is also used to treat malignant hyperthermia.  This drug interferes with Ca2+ release from the sarcoplasmic reticulum; benefit may not be apparent for a week or more.  The major adverse effects of dantrolene are muscle weakness, which may limit therapy, and sedation. Long-term use can result in hepatotoxicity that may be fatal. Hepatic function should be monitored during treatment.  Baclofen [Lioresal]  Baclofen is an analogue of γ-aminobutyric acid (GABA). It is a GABAB-receptor agonist that hyperpolarizes neurons to inhibit synaptic transmission in the spinal cord.  Adverse effects include some drowsiness and an increased frequency of seizures in epileptic patients.  Benzodiazepines (see Chapter 5) P.42  Benzodiazepines such as diazepam act on the spinal cord and CNS to facilitate GABA activity.  The major adverse effect is sedation.  MARC IMHOTEP CRAY, M.D. © 2009 24 VI. Sympathomimetic Drugs  Action and chemical structure o These drugs act either directly or indirectly to activate postjunctional and prejunctional adrenoceptors to mimic the effects of endogenous catecholamines such as epinephrine and norepinephrine. Their actions can generally be predicted from the type and location of the receptors with which they interact and whether or not they cross the blood–brain barrier to enter the CNS. o Indirectly acting agents either act within nerve endings to increase the release of stored catecholamines or at the prejunctional membrane to block the reuptake of catecholamines that have been released from nerve endings. o Sympathomimetic agents are usually derived from the parent compound β-phenylethylamine. Chemical modifications of the side chain or the catechol nucleus can markedly alter their relative selectivity and intrinsic activity at α-and β-receptors, their disposition, and their metabolism.  Pharmacologic effects (Table 2-8) o Cardiovascular system  β1-Receptor agonists increase the rate (chronotropic effect) and force (inotropic effect) of myocardial contraction and increase the conduction velocity through the AV node, with a decrease in the refractory period.  β2-Receptor agonists cause relaxation of vascular smooth muscle that may invoke a reflex increase in heart rate.  α1-Receptor agonists constrict smooth muscle of resistance blood vessels (e.g., in the skin and splanchnic beds), causing increased peripheral resistance and venous return. In normotensive patients (less effect in those with hypotension), the increased blood pressure may invoke a reflex baroreceptor vagal discharge and a slowing of the heart, with or without an accompanying change in cardiac output. Table 2.8 Direct Effects of Adrenoceptor Agonists Effector α1 α2 β1 β2 Heart Rate Increase Force Increase Arterioles (most) Constrict Dilate Blood pressure Increase Decrease Intestine Wall Relax Relax Relax Sphincters Contract Salivation Volume Increase Amylase Increase Pupil Dilate Bronchial smooth muscle Urinary bladder Relax Body Constrict Relax Sphincter Constrict Release of NE from nerves Decrease o P.43 MARC IMHOTEP CRAY, M.D. © 2009 25 o  α2-Receptor agonists reduce blood pressure by a prejunctional action on neurons in the CNS to inhibit sympathetic outflow. o Eye (see Table 2-3)  α-Receptor agonists contract the radial muscle of the iris and dilate the pupil (mydriasis). These drugs also increase outflow of aqueous humor from the eye.  β-Receptor antagonists decrease the production of aqueous humor. o Respiratory system effects include β2-receptor agonist–induced relaxation of bronchial smooth muscle and decreased airway resistance. o Gastrointestinal tract  α-Receptor and β-receptor agonists relax gastrointestinal smooth muscle. α-Receptor agonists reduce the release of ACh and other transmitters from intramural nerves by a prejunctional action; β-receptors are located directly on smooth muscle.  α1-Receptor agonists contract gastrointestinal sphincters. o Metabolic and endocrine effects  β-Receptor agonists increase liver and skeletal muscle glycogenolysis and increase lipolysis in fat cells (β3).  β-Receptor agonists increase, and α2-receptor agonists decrease, insulin secretion. o Genitourinary tract effects include β2-receptor agonist–induced relaxation of uterine smooth muscle and the bladder wall. α-Receptor agonists constrict the bladder wall (α1).  Specific sympathomimetic drugs are selected for use depending on the duration of action, route of administration, and also the specific effect on a particular tissue, which in turn depends on the tissue population of adrenoceptor subtypes. o Epinephrine and norepinephrine  Epinephrine and norepinephrine are poorly absorbed from the GI tract and do not enter the CNS to any appreciable extent. Absorption of epinephrine from subcutaneous sites is slow because of local vasoconstriction. Although rarely used, nebulized and inhaled solutions and topical preparations of epinephrine are available. Epinephrine and norepinephrine are most often administered intravenously (with caution to avoid cardiac arrhythmias or local tissue necrosis).  These drugs are metabolized extensively by enzymes in the liver. Catechol-O-methyl transferase (COMT) methylates the meta-hydroxyl group of the catechol, and monoamine oxidase (MAO) removes the amine group of the side chain. Metabolites are excreted by the kidney.  Epinephrine and norepinephrine actions at neuroeffector junctions are terminated primarily by active uptake into sympathetic nerve terminals and subsequent active transport into storage vesicles. Actions are also partially terminated at neuroeffector junctions by metabolism by extraneuronal COMT and intraneuronal MAO.  Epinephrine  Epinephrine activates β1-, β2-, and α-adrenoceptors.  Epinephrine administration in humans increases systolic pressure as a result of positive inotropic and chronotropic effects on the heart (β1-receptor activation) and generally results in decreased total peripheral resistance and MARC IMHOTEP CRAY, M.D. © 2009 26 decreased diastolic pressure due to vasodilation in the vascular bed of skeletal muscle (β2-receptor activation) that overcomes the vasoconstriction produced in most other vascular beds, including the kidney (α-receptor activation). The mean arterial pressure may increase slightly, decrease, or remain unchanged, depending on the balance of effects on systolic and diastolic pressure.  At high doses, epinephrine causes vasoconstriction in the vascular bed of skeletal muscle (α-receptor activation).  Epinephrine increases coronary blood flow as a result of increased cardiac workload; it may precipitate angina in patients with coronary insufficiency.  Epinephrine increases the drainage of aqueous humor (α-receptor activation) and reduces pressure in open-angle glaucoma. It dilates the pupil (mydriasis) by contraction of the radial muscle of the eye (α-receptor activation). P.44  Epinephrine relaxes bronchial smooth muscle (β2-receptor activation).  Norepinephrine  Norepinephrine activates β1-receptors (it is equipotent to epinephrine) and α-receptors (it is slightly less potent than epinephrine). It has little activity at β2-receptors.  Norepinephrine increases total peripheral resistance and diastolic blood pressure to a greater extent than epinephrine because of its vasoconstrictor activity and lack of effect on β2-receptors in the skeletal muscle vascular bed.  Norepinephrine increases systolic blood pressure and mean arterial pressure.  It has a direct stimulant effect on heart rate, but this is overcome by reflex baroreceptor-mediated vagal bradycardia.  Norepinephrine is rarely used therapeutically. o Dopamine [Intropin]  Dopamine activates peripheral β1-adrenoceptors to increase heart rate and contractility.  Dopamine activates prejunctional and postjunctional dopamine D1-receptors in the renal, coronary, and splanchnic vessels to reduce arterial resistance and increase blood flow. Prejunctionally, dopamine inhibits norepinephrine release.  At low doses, dopamine has a positive inotropic effect and increases systolic pressure, with little effect on diastolic pressure or mean blood pressure. MARC IMHOTEP CRAY, M.D. © 2009 27  At higher doses, dopamine activates α-receptors and causes vasoconstriction, with a reflex decrease in heart rate.  Fenoldopam [Corlopam] is a selective dopamine D1-receptor agonist used to treat severe hypertension. o β-Adrenoceptor agonists  Dobutamine  Dobutamine is a synthetic catecholamine that is related to dopamine.  Dobutamine has a relatively selective effect on β1-receptors and no effect on dopamine receptors.  This drug increases cardiac output with limited vasodilating activity and reflex tachycardia.  Dobutamine is administered by IV infusion because of its short half-life (t1/2 = 2 min).  Terbutaline [Brethine, Bricanyl], albuterol [Proventil, Ventolin], metaproterenol [Alupent], pirbuterol [Maxair], levalbuterol [Xenopex], bitolterol [Tornalate], salmeterol [Serevent], and formoterol [Foradil]  These drugs are more selective β2-receptor agonists that relax bronchial smooth muscle with fewer cardiac effects and longer duration of action than epinephrine.  Selectivity is lost at high concentrations.  Isoproterenol [Isuprel]  Isoproterenol activates β-receptors with little activity on α-receptors.  Isoproterenol dilates bronchial smooth muscle.  This drug increases heart rate and contractility and causes vasodilation in skeletal muscle vascular beds with decreased total peripheral resistance and decreased diastolic blood pressure.  It is infrequently used because of the availability of selective β2-adrenoceptor agonists. o α-Adrenoceptor agonists  Phenylephrine, methoxamine [Vasoxyl], and metaraminol [Aramine]  These drugs produce effects primarily by direct α1-receptor stimulation that results in vasoconstriction, increased total peripheral resistance, and increased systolic and diastolic pressure. Metaraminol also has indirect activity; it is taken up and released at sympathetic nerve endings, where it acts as a false neurotransmitter. It also releases epinephrine.  Because they are not metabolized by COMT, these drugs are less potent but have longer durations of action than catecholamines.  Midodrine [ProAmatine] is a prodrug that is hydrolyzed to the α1-adrenoceptor agonist desglymidodrine.  Xylometazoline [Otrivin] and oxymetazoline [Afrin] P.45 MARC IMHOTEP CRAY, M.D. © 2009 28  These drugs have selective action at α-receptors.  At high doses, these drugs may cause clonidine-like effects because of their action in the CNS.  Clonidine [Catapres], methyldopa [Aldomet], guanabenz [Wytensin], and guanfacine [Tenex]  These drugs directly or indirectly activate prejunctional and, probably, at postjunctional α2-receptors in the vasomotor center of the medulla to reduce sympathetic tone.  These drugs reduce blood pressure, with a decrease in total peripheral resistance and minimal long-term effects on cardiac output and heart rate.  Methyldopa is a prodrug that is metabolized to the active agents α-methylnorepinephrine (and α-methyldopamine) in nerve endings. At higher, nontherapeutic doses, it activates peripheral α-receptors to cause vasoconstriction. o Other adrenoceptor agonists  Ephedrine and mephenteramine  These drugs act indirectly to release norepinephrine from nerve terminals and have some direct action on adrenoceptors.  Ephedrine and mephenteramine have effects similar to those of epinephrine, but they are less potent; they have a longer duration of action because they are resistant to metabolism by COMT and MAO.  These drugs are effective orally and, unlike catecholamines, penetrate the brain and can produce CNS stimulation.  Ephedrine is found in the herbal medication Ma-huang.  Pseudoephedrine [Sudafed], an isomer of ephedrine, is a component of over-the-counter (OTC) nasal decongestants.  After continued use, tachyphylaxis may develop to their peripheral effects.  Amphetamine, dextroamphetamine [Dexedrine], methamphetamine [Desoxyn], phendimetrazine [Preludin], modafinil [Provigil], methylphenidate [Ritalin], pemoline [Cylert], and hydroxyamphetamine [Paredrine] (see Chapter 5)  These drugs produce effects similar to those of ephedrine, with indirect and some direct activity.  Dextroamphetamine has more CNS-stimulatory activity than the levo isomer, which has more cardiovascular activity.  These drugs are well absorbed and, except for hydroxyamphetamine, enter the CNS readily and have marked stimulant activity.  Therapeutic uses (Table 2-9) o Cardiovascular system  Phenylephrine, methoxamine, and norepinephrine and other direct-acting α-receptor sympathomimetic drugs, are used for short-term hypotensive emergencies when there is inadequate perfusion of the heart and brain such as during severe hemorrhage.  Ephedrine and midodrine are used to treat chronic orthostatic hypotension. MARC IMHOTEP CRAY, M.D. © 2009 29  The use of sympathomimetic agents in most forms of shock is controversial and should be avoided. Further vasoconstriction may be harmful.  Low-to-moderate doses of dobutamine or dopamine may be useful in cases of cardiogenic or septic shock because they increase cardiac output with minimal vasoconstrictive effect on the peripheral vasculature.  Epinephrine is used to reverse hypotension and angioedema associated with anaphylactic shock.  Dobutamine is used to treat congestive heart failure.  Isoproterenol and epinephrine have been used for temporary emergency treatment of cardiac arrest and heart block because they increase ventricular automaticity and rate and increase AV conduction.  Epinephrine is commonly used in combination with local anesthetics (1:200,000) during infiltration block to reduce blood flow. α-Receptor agonist activity causes local vasoconstriction, which prolongs local anesthetic action and allows the use of lower P.46 doses with reduced chance of toxicity. Phenylephrine and norepinephrine have also been used. Table 2.9 Selected Therapeutic Uses of Adrenoceptor Agonists Clinical Condition/Application Agonist Receptor Hypotensive emergency Phenylephrine; methoxamine; norepinephrine α1 Orthostatic hypotension Ephedrine; midodrine α1 Anaphylactic shock Epinephrine α and β Heart block, cardiac arrest Isoproterenol; epinephrine β1 Congestive heart failure Dobutamine β1 Infiltration nerve block Epinephrine α1 Hay fever and rhinitis Phenylephrine; OTCa α1 Asthma Metaproterenol; terbutaline; albuterol β2 aOver-the-counter preparations.  Epinephrine is used during spinal anesthesia to maintain blood pressure, as is phenylephrine, and topically to reduce superficial bleeding. o Respiratory system  Phenylephrine and other short-and longer acting α-adrenoceptor agonists, including oxymetazoline, xylometazoline, tetrahydrozoline [Tyzine], ephedrine and pseudoephedrine are used for symptomatic relief of hay fever and rhinitis of the common cold. Many are available as OTC medications. Long-term use may result in ischemia and rebound hyperemia, with development of chronic rhinitis and congestion. MARC IMHOTEP CRAY, M.D. © 2009 30  Metaproterenol, terbutaline, albuterol, bitolterol, and other β2-adrenoceptor agonists are preferred for treating asthma. Epinephrine is also used for management of acute bronchospasm.  Epinephrine is administered subcutaneously to treat bronchospasm, congestion, angioedema, and cardiovascular collapse of anaphylaxis. o Eye  Phenylephrine facilitates examination of the retina because of its mydriatic effect. It is also used for minor allergic hyperemia of the conjunctiva.  α2-Receptor agonists (apraclonidine [Lopidine] and brimonidine [Alphagan]) that lower intraocular pressure by increasing aqueous outflow (epinephrine and dipivefrin [Propine] are rarely used) have been largely supplanted by β-adrenoceptor blockers and prostaglandin analogues for treatment of chronic open-angle glaucoma. o CNS  Amphetamine and related analogues (e.g., modafinil), are used to treat narcolepsy (controversial) because of their arousal effects and their ability to increase the attention span; as occasional adjunct therapy for obesity because of their anorexiant effects; and to treat attention-deficit hyperactivity disorder in children (e.g., methylphenidate).  Hydroxyamphetamine and phenylephrine are used for the diagnosis of Horner syndrome.  Dexmedetomidine [Precedex], a novel, selective α2-adrenoceptor agonist that acts centrally, is used intravenously as a sedative in patients hospitalized in intensive care settings. o Other uses include ritodrine and terbutaline to suppress premature labor by relaxing the uterus, although the efficacy of these drugs is controversial.  Adverse effects and toxicity o The adverse effects of sympathomimetic drugs are generally extensions of their pharmacologic activity. o Overdose with epinephrine or norepinephrine or other pressor agents may result in severe hypertension, with possible cerebral hemorrhage, pulmonary edema, and cardiac arrhythmia. Milder effects include headache, dizziness, and tremor. Increased cardiac workload may result in angina or myocardial infarction in patients with coronary insufficiency. P.47 o Phenylephrine should not be used to treat closed-angle glaucoma before iridectomy as it may cause increased intraocular pressure. o Sudden discontinuation of an α2-adrenoceptor agonist may cause withdrawal symptoms that include headache, tachycardia, and a rebound rise in blood pressure. o Drug abuse may occur with amphetamine and amphetamine-like drugs. o Drug interactions  Tricyclic antidepressants block catecholamine reuptake and may potentiate the effects of norepinephrine and epinephrine. MARC IMHOTEP CRAY, M.D. © 2009 31  Some halogenated anesthetic agents and digitalis may sensitize the heart to β-receptor stimulants, resulting in ventricular arrhythmias. VII. Adrenergic Receptor Antagonists These drugs interact with either α-or β-adrenoceptors to prevent or reverse the actions of endogenously released norepinephrine or epinephrine or exogenously administered sympathomimetic agents.  α-Adrenoceptor antagonists o Pharmacologic effects  The pharmacologic effects of α-adrenoceptor antagonists are predominantly cardiovascular and include lowered peripheral vascular resistance and blood pressure. These agents prevent pressor effects of α-receptor agonists.  α-Adrenoceptor antagonists convert the pressor action of sympathomimetic agents with both α-and β-adrenoceptor agonist activity to a depressor response; this is referred to as epinephrine reversal. o Specific drugs (Table 2-10)  Phentolamine [Regitine] is an intravenously administered, short-acting competitive antagonist at both α1-and α2-receptors. It reduces peripheral resistance and decreases blood pressure. Tolazoline [Priscoline], a drug similar to phentolamine, is rarely used.  Prazosin [Minipress]  Prazosin is the prototype of competitive antagonists selective for α1-receptors. Others include terazosin [Hytrin], doxazosin [Cardura], and tamsulosin [Flomax].  Prazosin reduces peripheral resistance and blood pressure.  This drug is administered orally. Prazosin has a slow onset (2–4 h) and a long duration of action (10 h) and is extensively metabolized by the liver (50% during first pass).  Labetalol [Normodyne and Trandate]  Labetalol is a competitive antagonist (partial agonist) that is relatively selective for α1-receptors and also blocks β-receptors.  Labetalol reduces heart rate and myocardial contractility, decreases total peripheral resistance, and lowers blood pressure.  This drug is administered orally or intravenously and undergoes extensive first-pass metabolism.  Phenoxybenzamine [Dibenzyline]  Phenoxybenzamine is a noncompetitive, irreversible α1-receptor antagonist.  Phenoxybenzamine binds covalently, resulting in a long-lasting (15–50 h) blockade. o Therapeutic uses (Table 2-10)  Overview  α1-Adrenoceptor antagonists are used most often to treat hypertension and urinary obstruction of benign prostatic hypertrophy.  α2-Adrenoceptor antagonists have no important therapeutic uses.  Pheochromocytoma MARC IMHOTEP CRAY, M.D. © 2009 32  Pheochromocytoma is a tumor of the adrenal medulla that secretes excessive amounts of catecholamines. Symptoms include hypertension, tachycardia, and arrhythmias. P.48 P.49 Table 2.10 Therapeutic Uses of Selected Adrenoceptor Antagonists Drug Receptor Features Major Uses Phentolaminea α1 and α2 Short duration of action (1–2 h) Hypertension of pheochromocytoma Phenoxybenzaminea Long duration of action (15–50 h) Hypertension of pheochromocytoma Prazosina α1 Minimal reflex tachycardia Mild-to-moderate hypertension (often with a diuretic or a βadrenoceptor antagonist); severe congestive heart failure (with a cardiac glycoside and a diuretic) Terazosin Mild-to-moderate hypertension Doxazosin Mild-to-moderate hypertension Propranolola β1 and β2 Local anesthetic activity Hypertension; angina; pheochromocytoma, cardiac arrhythmias; migraine headache; hypertrophic subaortic stenosis Timolol Hypertension; glaucoma Metipranolol Glaucoma Levobunolol Glaucoma MARC IMHOTEP CRAY, M.D. © 2009 33 Nadolol Long duration of action (15–25 h) Hypertension; angina Pindolol Partialβ2-receptor agonist activityb; Hypertension; angina Penbutolol Partialβ2-receptor agonist activityb; mild-to-moderate hypertension Hypertension; angina Carteolol Partial b2-receptor agonist activityb; excreted unchanged Hypertension; angina; glaucoma Metoprolola β1>β2 Patient bioavailability is variable; extended release form available Hypertension; angina Atenolol Eliminated by the kidney Hypertension; angina Esmolol Ultrashort acting (10 min) Supraventricular tachycardia Betaxolol Long duration of action (15–25 h) Glaucoma; hypertension Acebutolol Partial agonistb Hypertension; ventricular arrhythmias Labetalola β1, β2, and α1 Partial agonistb; rapid blood pressure reduction; local anesthetic activity Mild-to-severe hypertension; hypertensive emergencies aDrugs listed in boldface type are considered prototype drugs. bLower blood pressure without significant reduction in cardiac output or resting heart rate; also do not elevate triglyceride levels or decrease high-density lipoprotein cholesterol. MARC IMHOTEP CRAY, M.D. © 2009 34  Phentolamine and phenoxybenzamine are used to treat the tumor in the preoperative stage; they also are used for long-term management of inoperable tumors.  β-Receptor antagonists are often used to prevent the cardiac effects of excessive catecholamines after an a α-receptor blockade is established.  Adrenoceptor antagonists, particularly labetalol, are occasionally used to reverse hypertensive crisis due to sudden increase in α-receptor stimulation caused by, for example, a pheochromocytoma or an overdose with a sympathomimetic agonist.  Prazosin and labetalol are used to treat essential hypertension.  α1-Adrenoceptor antagonists, such as prazosin, terazosin, and doxazosin, are used to treat urinary obstruction of benign prostatic hypertrophy (BPH). Tamsulosin may have greater efficacy due to its selective action at α1A-receptors.  Other uses of α-adrenoceptor antagonists (e.g., phentolamine) include reversible peripheral vasospasm like Raynaud syndrome, and erectile dysfunction (in combination with papaverine). o Adverse effects  Adverse effects of phentolamine include postural hypotension, reflex tachycardia, arrhythmia, angina, and diarrhea. This drug should be used cautiously in patients with a peptic ulcer or with coronary artery disease.  Prazosin, terazosin, and doxazosin produce postural hypotension and bradycardia on initial administration; these drugs produce no significant tachycardia.  Adverse effects of labetalol include postural hypotension and GI disturbances. Bradycardia occurs with overdose. Labetalol produces fewer adverse effects on the bronchi and cardiovascular system than selective β-receptor antagonists.  β-Adrenoreceptor antagonists o Pharmacologic effects  Cardiovascular system  β-Adrenoreceptor antagonists lower blood pressure, possibly because of their combined effects on the heart, the renin–angiotensin system, and the CNS.  These drugs reduce sympathetic-stimulated increases in heart rate and contractility and cardiac output.  β-Adrenoreceptor antagonists lengthen AV conduction time and refractoriness and suppress automaticity.  Initially, they may increase peripheral resistance. However, long-term administration results in decreased peripheral resistance in patients with hypertension.  β-Adrenoreceptor antagonists reduce renin release.  Respiratory system  β-Adrenoreceptor antagonists increase airway resistance as a result of β2-receptor blockade.  This respiratory effect is more pronounced in asthmatics because of unopposed, compensatory, reflex sympathomimetic α-receptor activity resulting from decreased cardiac output. MARC IMHOTEP CRAY, M.D. © 2009 35  Eye  β-Adrenoreceptor antagonists decrease the production of aqueous humor, resulting in reduced intraocular pressure.  Other activities  β-Adrenoreceptor antagonists inhibit lipolysis (β3).  These drugs inhibit glycogenolysis (β2) in the liver (they may impede recovery from the hypoglycemic effect of insulin).  These drugs decrease high-density lipoprotein (HDL) levels.  Some β-adrenoceptor antagonists have local anesthetic action, including propranolol and labetalol. o Specific drugs (Table 2-10)  Overview  Propranolol is the prototype β-adrenoreceptor antagonist. P.50  These drugs have an antihypertensive effect that is slow to develop (the mechanism is unclear).  β-Adrenoreceptor antagonists are absorbed well after oral administration. Including propranolol, many have low bioavailability (<50%) because of extensive first-pass metabolism; marked interpatient variability is seen, particularly with metoprolol.  With the exceptions of esmolol (10 min) and nadolol and betaxolol (15–25 h), most have a t1/2 of 3–12 hours.  Propranolol [Inderal]  Propranolol is a competitive antagonist at β1-and β2-receptors.  Propranolol is used in long-term treatment of hypertension, but it is not useful for hypertensive crisis.  This drug is used to treat supraventricular and ventricular arrhythmias and is administered intravenously for the emergency treatment of arrhythmias.  Propranolol is 90% bound to plasma proteins.  This drug is cleared by hepatic metabolism and, therefore, has prolonged action in the presence of liver disease.  Propranolol is also available in sustained-release preparation.  Metoprolol [Lopressor], betaxolol [Betoptic], bisoprolol [Zebeta], atenolol [Tenormin], acebutolol [Sectral], and esmolol [Brevibloc]  These drugs are somewhat selective β1-receptor antagonists that may offer some advantage over nonselective β-adrenoceptor antagonists to treat cardiovascular disease in asthmatic patients, although cautious use is still warranted.  Atenolol is eliminated primarily by the kidney and undergoes little hepatic metabolism; it has little local anesthetic activity; it enters the CNS poorly.  Acebutolol has partial agonist activity.  Betaxolol is used topically for chronic open-angle glaucoma. MARC IMHOTEP CRAY, M.D. © 2009 36  Esmolol is ultrashort acting (t1/2 = 10 min) because of extensive plasma hydrolysis by esterases; it is administered by IV infusion.  Metoprolol is also available in sustained-release preparation.  Labetalol [Normodyne and Trandate], Carvedilol [Coreg]  Labetalol is a partial agonist that blocks β-receptors and α1-receptors (3:1 to 7:1 ratio). Carvedilol also has mixed activity but is equiactive at β-receptors and α1-receptors.  Labetalol reduces heart rate and myocardial contractility, decreases total peripheral resistance, and lowers blood pressure.  This drug is administered orally or intravenously and undergoes extensive first-pass metabolism.  Timolol [Blocadren], levobunolol [Betagan], nadolol [Corgard], and sotalol [Betapace]  These drugs are nonselective β-receptor antagonists.  Timolol and levobunolol have excellent ocular effects when applied topically for glaucoma. Like propranolol, these drugs have no local anesthetic activity. Metipranolol [OptiPranolol] is also used to treat glaucoma.  Sotalol additionally prolongs the cardiac action potential and is used to treat arrhythmias.  Pindolol [Visken], carteolol [Cartrol], and penbutolol [Levatol] are nonselective antagonists with partial β2-receptor agonist activity.  Carteolol is used topically to treat open-angle glaucoma. It is excreted unchanged. o Therapeutic uses (see Table 2-10)  Cardiovascular system (also see Chapter 4)  β-Adrenoreceptor antagonists are used to treat hypertension, often in combination with a diuretic or vasodilator.  These drugs reduce incidence of myocardial infarction.  These drugs provide prophylaxis for supraventricular and ventricular arrhythmias.  β-Adrenoreceptor antagonists provide prophylaxis for angina pectoris. Long-term use may prolong survival after acute myocardial infarction. P.51  Propranolol relieves angina, palpitations, dyspnea, and syncope in obstructive cardiomyopathy. This effect is thought to be related to the slowing of ventricular ejection and decreased resistance to outflow.  Eye  Topical application of timolol, betaxolol, levobunolol, and carteolol reduces intraocular pressure in glaucoma.  Sufficient timolol can be absorbed after topical application to increase airway resistance and decrease heart rate and contractility. MARC IMHOTEP CRAY, M.D. © 2009 37  Other uses  Propranolol is used to control clinical symptoms of sympathetic overactivity in hyperthyroidism by an unknown mechanism, perhaps by inhibiting conversion of thyroxine to triiodothyronine.  Propranolol and others may be beneficial in the prophylaxis of migraine headache by an unknown mechanism.  Propranolol relieves acute anxiety and panic symptoms by inhibiting overactivity of the sympathetic nervous system. o Adverse effects and contraindications  All agents  β-Adrenoreceptor antagonists should be administered with extreme caution in patients with preexisting compromised cardiac function because they can precipitate heart failure or heart block.  These drugs may augment insulin action in diabetics and mask tachycardia associated with hypoglycemia.  β-Adrenoreceptor antagonists may mask the signs of developing hyperthyroidism.  After abrupt withdrawal, adrenoceptor ―supersensitivity‖ and increased risk of angina and arrhythmias may occur. Tapered withdrawal is recommended.  Nonselective adrenoceptor antagonists  These drugs may cause bronchoconstriction, and thus they are contraindicated for asthmatics. Patients with chronic obstructive lung disease are particularly susceptible.  These drugs should be used cautiously in patients with peripheral vascular disease.  β1-Selective antagonists should also be used cautiously to treat asthmatics and patients with peripheral vascular disease because they have some β2-receptor antagonist activity.  Propranolol, and other β-receptor blockers, cause sedation, sleep disturbances, and depression. P.52 MARC IMHOTEP CRAY, M.D. © 2009 38 Drug Summary Table Direct-Acting Cholinoceptor Agonists Acetylcholine [Miochol-E] Bethanechol [Urecholine] Carbachol [Generic] Cevimeline [Evoxac] Methacholine [Mecholyl] Pilocarpine [Generic] Indirect-Acting Cholinoceptor Agonists Ambenonium [Mytelase] Demecarium [Humorsol] Echothiophate [Phospholine] Edrophonium [Tensilon] Neostigmine [Prostigmin] Physostigmine [Eserine, Antilirium] Pyridostigmine [Mestinon, Regonol] Muscarinic Cholinoceptor Antagonists Atropine [generic] Clidinium [Quarzan] Cyclopentolate [Cyclogyl] Dicyclomine [Bentyl] Glycopyrrolate [Robinul] Homatropine [generic] Ipratropium [Atrovent] Mepenzolate [Cantil] Methantheline [Banthine] Oxybutynin [Ditropan] Propantheline [Pro-Banthine] Scopolamine [generic] Tolterodine [Detrol] Tridihexethyl [Pathilon] Tropicamide [generic] Ganglionic Blocking Drugs Mecamylamine [Inversine] Trimethaphan [Arfonad] Skeletal Muscle Relaxants Atracurium [generic] Cisatracurium [Nimbex] Metocurine [Metubine] Mivacurium [Mivacron] Pancuronium [Pavulon] Succinylcholine [Anectine] Tubocurarine [generic] Vecuronium [Norcuron] Spasmolytic Drugs Baclofen [Lioresal] Dantrolene [Dantrium] Sympathomimetic Drugs Albuterol [Proventil, Ventolin] Amphetamine [generic] Apraclonidine [Lopidine] MARC IMHOTEP CRAY, M.D. © 2009 39 Bitolterol [Tornalate] Brimonidine [Alphagan] Clonidine [Catapres] Dexmedetomidine [Precedex] Dextroamphetamine [Dexedrine] Dobutamine [Dobutrex] Dopamine [Intropin] Ephedrine [generic] Epinephrine [generic] Formoterol [Foradil] Guanabenz [Wytensin] Guanfacine [Tenex] Hydroxyamphetamine [Paredrine] Isoproterenol [Isuprel] Levalbuterol [Xopenex] Mephenteramine [Wyamine] Metaproterenol [Alupent] Metaraminol [Aramine] Methamphetamine [Desoxyn] Methoxamine [Vasoxyl] Methyldopa [Aldomet] Methylphenidate [Ritalin] Midodrine [ProAmatine] Modafinil [Provigil] Norepinephrine [generic] Pemoline [Cylert] Phendimetrazine [Preludin] Phenylephrine [generic] Pirbuterol [Maxair] Pseudoephedrine [Sudafed] Salmeterol [Serevent] Terbutaline [Brethine, Bricanyl] Tetrahydrozoline [Tyzine] Adrenergic Receptor Antagonists Acebutolol [Sectral] Atenolol [Tenormin] Betaxolol [Betoptic] Bisoprolol [Zebeta] Carteolol [Cartrol] Carvedilol [Coreg] Doxazosin [Cardura] Esmolol [Brevibloc] Labetalol [Normodyne, Trandate] Levobunolol [Betagan] Metipranolol [OptiPranolol] Metoprolol [Lopressor] Nadolol [Corgard] Penbutolol [Levatol] Phenoxybenzamine [Dibenzyline] Phentolamine [Regitine] Pindolol [Visken] MARC IMHOTEP CRAY, M.D. © 2009 40 Prazosin [Minipress] Propranolol [generic] Sotalol [Betapace] Tamsulosin [Flomax] Terazosin [Hytrin] Timolol [Blocadren] Tolazoline [Priscoline]